Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions

Peritoneal Dialysis International

Volumn 21, Issue SUPPL. 3, 2001, Pages

  Cooker, Laurinda A ^a   Luneburg, Patricia ^a   Holmes, Clifford J ^a   Jones, Suzanne ^a   Topley, Nicholas ^a   O'Donoghue, D ^a   Frenken, I ^a   Brown, E ^a   Walls, J ^a   Pedersen, F B I ^a   Freese, P ^a   Gokal, R ^a   Junor, B ^a   Maiorca, R ^a   Weiss, L ^a   Farrington, K ^a   Kristiensen, J ^a   Ahlmen J ^a   Struijk, D ^a   Brouwer, R ^a   Ryckelynck, J P ^a   Williams, J D ^a   Hopwood, A M ^a   more..

^a BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Bicarbonate; Biocompatibility; Dialysate; Effluent markers

Indexed keywords

BICARBONATE; BUFFER; GLUCOSE DEGRADATION PRODUCT; INTERLEUKIN 6; LACTIC ACID; PERITONEAL DIALYSIS FLUID; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ACIDITY; ADULT; AGED; ANGIOGENESIS; ARTICLE; BIOCOMPATIBILITY; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FILTRATION; FREEZING; HOMEOSTASIS; HUMAN; IN VITRO STUDY; INFLAMMATION; MAJOR CLINICAL STUDY; PERITONEUM; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SAMPLE;

ADULT; AGED; BICARBONATES; BIOCOMPATIBLE MATERIALS; BUFFERS; DIALYSIS SOLUTIONS; ENDOTHELIAL GROWTH FACTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-6; LACTIC ACID; LYMPHOKINES; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONEUM; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 16744362363     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Reduced glucose degradation products in bicarbonate/lactate-buffered peritoneal dialysis solutions produced in two-chambered bags
2. Longitudinal follow-up of CA125 in peritoneal effluent
3. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels
4. Growth factors in continuous ambulatory peritoneal dialysis effluent. Their relation with peritoneal transport of small solutes
5. Intraperitoneal hyaluronan production in stable continuous ambulatory peritoneal dialysis patients
6. Growth factors VEGF and TGF-beta1 in peritoneal dialysis
7. Intraperitoneal secretion of interleukin-6 during continuous ambulatory peritoneal dialysis
8. Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis
9. Appearance of tumor necrosis factor-alpha and soluble TNF-receptors I and II in peritoneal effluent of CAPD
10. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis
11. Vascular endothelial growth factor, a potent and selective angiogenic agent
12. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution-clinical benefits
13. Role of the peritoneal membrane in the control of inflammation in the peritoneal cavity
14. Human peritoneal mesothelial cells synthesize interleukin-6: Induction by IL-1β and TNF-α
15. Human peritoneal mesothelial cells produce many cytokines (granulocyte colony-stimulating factor [CSF], granulocyte-monocyte-CSF, macrophage-CSF, interleukin-1 [IL-1], and IL-6) and are activated and stimulated to grow by IL-1
16. Expression of human hyaluronan synthases in response to external stimuli
17. Hyaluronan synthases
18. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products
19. Peritoneal dialysis effluent, cytokine levels, and peritoneal mesothelial cell viability in CAPD: A possible relationship
20. The soluble interleukin 6 receptor: Mechanisms of production and implications in disease
21. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF
22. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation
23. Inflammatory and atherosclerotic interactions in the depleted uremic patient
24. Bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNF-alpha secretion
25. In vivo exposure to bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improves ex vivo peritoneal macrophage function
26. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis
27. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: Role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis
28. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure
29. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration
30. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis